Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Bio-Matrix Scientific Group, Inc.Financial_Report.xls
EX-31.2 - CERTIFICATION - Bio-Matrix Scientific Group, Inc.bmsn_ex312.htm
EX-32.2 - CERTIFICATION - Bio-Matrix Scientific Group, Inc.bmsn_ex322.htm
EX-31.1 - CERTIFICATION - Bio-Matrix Scientific Group, Inc.bmsn_ex311.htm
EX-10.1 - CONVERTIBLE PROMISSORY NOTE - Bio-Matrix Scientific Group, Inc.bmsn_ex101.htm
EX-32.1 - CERTIFICATION - Bio-Matrix Scientific Group, Inc.bmsn_ex321.htm



SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q


Quarterly Report under Section 13 or 15 (d) of

Securities Exchange Act of 1934


For Period ended March 31, 2012


Commission File Number 0-32201


BIO-MATRIX SCIENTIFIC GROUP, INC.

(Exact name of registrant as specified in its charter)


DELAWARE

33-0824714

(State of Incorporation)

(I.R.S. Employer Identification No.)

 

 

4700 Spring Street, Suite 304, La Mesa, California

91942

(Address of Principal Executive Offices)

(Zip Code)


(619) 398-3517

(Registrant's telephone number, including area code)



Check whether the registrant (1) has filed all reports required to be filed by

Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding

12 months (or for such shorter period that the registrant was required to file

such reports), and (2) has been subject to such filing requirements for the past

90 days. Yes [X]   No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

[  ]  Large accelerated filer

[  ]  Accelerated filer

 

 

[  ]  Non-accelerated filer

[X]  Smaller reporting company


Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934) (check one): Yes [  ]   No   [X]

 

There were 72,189,747 shares of Common Stock outstanding as of March 31, 2012.






 






PART I - FINANCIAL INFORMATION


BIOMATRIX SCIENTIFIC GROUP, INC.

 A Development Stage Company

 CONSOLIDATED BALANCE SHEET

 


 

March 31,

September 30,

 

2012

2011

ASSETS

(unaudited)

 

 CURRENT ASSETS

 

 

 

 Cash

$  244

$   331

 

 Prepaid Expenses

39,925

39,925

 

      Total Current Assets

40,169

40,256

 

 

 

 PROPERTY & EQUIPMENT (Net of Accumulated Depreciation)

20,789

20,789

 

 

 

 OTHER ASSETS

 

 

 

 Deposits

4,200

4,200

 

 Investment in Subsidiary  

41,336,361

41,735,443

 

41,340,561

41,739,643

 

 

 

 TOTAL ASSETS

$41, 401,519

$41, 800,688

 

 

 

 

 LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 CURRENT LIABILITIES

 

 

 

 Accounts Payable

$ 130,507

$130,507

 

 Notes Payable

189,732

169,575

 

 Accrued Payroll  

777,000

627,000

 

 Accrued Payroll Taxes

23,780

23,780

 

 Accrued Interest

203,869

154,930

 

 Accrued Expenses

5,000

5,000

 

 Convertible Note Payable Net of  Unamortized Discount

372,694

313,701

 

 Due to Affiliate

59,740

59,500

 

 Current portion, note payable to affiliated party

1,000

1,000

 

      Total Current Liabilities

1,763,322

1,484,993

 

 

 

 STOCKHOLDERS EQUITY

 

 

 

 Preferred Stock ($.0001 par value) 20,000,000 shares authorized;

 

 

 

 20,000,000 shares authorized; 1,963,821 issues and outstanding as of

 

 

 

     September 30, 2011 and March 31,2012

197

197

 

Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized;

 

 

 

    725,409 issued and outstanding as of September 30, 2011 and

 

 

 

   March 31, 2012

73

73

 

 Common Stock ($.0001 par value) 500,000,000 shares authorized;

 

 

 

    72,189,747  issued and outstanding as of September 30, 2011 and  

 

 

 

    March  31, 2012

7,219

7,219

 

 Additional Paid in Capital

11,539,640

11,498,731

 

 Contributed Capital

509,355

509,355

 

 Retained Earnings (Deficit) accumulated during the development stage  

28,782,323

29,101,648

 

 Equity in Earnings (Loss) of subsidiary

(663,649)

(264,567)

 

 Deficit attributable to noncontrolling interest in subsidiary

(536,961)

(536,961)

 

 Total Stockholders' Equity

39,638,197

40,315,695

 

 

 

 TOTAL LIABILITIES & STOCKHOLDERS' EQUITY  

$41, 401,519

$41, 800,688


The accompanying Notes are an Integral Part of these Financial Statements



2






BIOMATRIX SCIENTIFIC GROUP, INC.

 A Development Stage Company

 CONSOLIDATED STATEMENT OF OPERATIONS

 (Unaudited)


 

 

 

 From Inception

 

 

 

 (August 2, 2005)

 

 For the Three Months Ended

 For the Six Months Ended

 through

 

March 31,

March 31,

 March  31,

 

2012

2011

2012

2011

2012

 REVENUES  

 

 

 

 

-

 

 

 

 

 

 

 COST AND EXPENSES

 

 

 

 

 

 

 Research and Development

 

 

 

51,826

1,255,171

 

 General and Administrative

76,665

100,697

189,743

385,392

6,293,065

 

 Depreciation and Amortization

 

 

 

 

2,668

 

 Consulting and Professional Fees

29,515

5,290

58,241

32,236

4,871,455

 

 Impairment of Goodwill and Intangibles

 

 

 

 

34,688

 

 Total Costs and Expenses

106,180

105,897

247,984

468,914

12,457,047

 

 

 

 

 

 

 OPERATING LOSS

(106,180)

(105,987)

(247,984)

(468,914)

(12,457,047)

 

 

 

 

 

 

 OTHER INCOME & (EXPENSES)

 

 

 

 

 

 

 Interest Expense

(34,162)

(14,019)

(48,939)

(34,212)

(407,474)

 

 Interest Expense attributable to  

 

 

 

 

 

 

    amortization of discount

(20,643)

 

(22,402)

 

(22,402)

 

 Interest Income

 

 

 

 

306

 

 Other Income

 

146,791

 

146,791

176,891

 

 Gain on de-consolidation of subsidiary

 

42,182,649

 

42,182,649

42,182,649

 

 Loss on sale of Available for Sale Securities

 

 

 

 

(487,900)

 

 Loss on disposal of Equipment

 

 

 

 

(510,782)

 

 Other Expense

 

 

 

 

(166)

 

 Other Losses attributable to subsidiary

 

(228,715)

 

(228,715)

(228,713)

 Total Other Income & (Expense)

(54,805)

42,086,706

(71,341)

42,066,503

40,702,409

 

 

 

 

 

 

 NET INCOME (LOSS)

(160,985)

41,980,719

(319,325)

41,597,599

28,245,362

 (Net Income) Loss attributable to

 

 

 

 

 

 

    noncontrolling interest

 

112,525

 

229,845

536,961

 NET INCOME (LOSS) before  

 

 

 

 

 

 

 equity in subsidiary losses

(160,985)

42,093,244

(319,325)

41,827,444

28,782,323

 Equity in Net Income (Loss)  

 

 

 

 

 

 

 of subsidiary

(343,749)

(101,838)

(399,082)

(101,838)

(663,649)

 

 

 

 

 

 

 NET INCOME (LOSS) attributable

 

 

 

 

 

 

  to common shareholders

$ (504,734)

$ 41,991,406

$ (718,407)

$41,725,606

$ 28,118,674

 BASIC  AND FULLY DILUTED

 

 

 

 

 

 

  EARNINGS (LOSS)

$ (0.0070)

$ 0.5890

$ (0.0100)

$ 0.5892

 

 Weighted average number of

 

 

 

 

 

 

  shares outstanding

72,189,747

71,237,366

72,189,747

70,816,121

 


The accompanying Notes are an Integral Part of these Financial Statements



3






BIO-MATRIX SCIENTIFIC GROUP, INC.  

 A Development Stage Company

 CONSOLIDATED STATEMENT OF CASH FLOWS

 (Unaudited)


 

 

 

 

 

 From Inception

 

 

 (August 2, 2005)

 

 For the Six months ended  

 through

 

March 31,

 March 31,

 

2012

2011

2012

 

 

 

 

 CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

 Net Income (loss)

(718,407)

41,725,606

28,118,674

 Adjustments to reconcile net Income to net cash

 

 

 

 

 (used in) provided by operating activities:

 

 

 

 

 Depreciation expense

 

 

2,667

 

 Stock issued for compensation to employees

 

71,440

1,186,342

 

 Stock issued for services rendered by consultants

 

62,400

4,083,130

 

 Stock issued for prepaid expenses

 

 

313,665

 

 Stock issued for interest

 

6,821

138,547

 Changes in operating assets and liabilities:

 

 

 

 

 (Increase) decrease in prepaid expenses

 

500

(39,925)

 

 Increase (Decrease) in Accounts Payable

 

(121,021)

130,508

 

 Increase (Decrease) in Accrued Expenses

198,939

13,135

1,039,585

 

Increase (Decrease) in Other Comprehensive Income

 

 

(50,000)

 

 (Increase) Decrease in Employee Receivable

 

1,396

 

 

 Increase (Decrease) in Due to Affiliate

240

73,500

59,740

 

 Non cash increase in Investment in Entest  

 

(42,000,000)

(42,000,000)

 

 Loss attributable to Non Controlling interest in

 

 

 

 

    subsidiary

 

(229,845)

(536,961)

 

 Equity in Loss of Entest

399,082

101,838

663,649

 Net Cash Provided by (Used in) Operating

 

 

 

 

 Activities

(120,146)

(294,230)

(6,890,379)

 

 

 

 

 CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 ( Increase) Decrease in Other Assets

 

22,366

(4,200)

 

 Purchases of fixed assets

 

 

(541,536)

 

 Disposal of Fixed Assets

 

 

7,300

 

 Loss on Disposal of Equipment

 

 

510,780

 

 Increase in Cash in Escrow

 

 

 

 Net Cash Provided by (Used in) Investing

 

 

 

 

 Activities

 

22,366

(27,656)

 

 

 

 

 CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 Preferred Stock issued for cash

 

 

339

 

 Common stock issued for cash

 

 

1,630

 

 Common Stock issued for Debt

 

89,992

1,296,053

 

 Common Stock issued for Accrued Salaries

 

 

424,500

 

 Common Stock issued for expenses

 

 

 

 

 Common stock issued in merger

 

 

 

 

 Additional paid in Capital

40,909

336,498

2,058,326

 

 Principal borrowings on Convertible Debentures

58,993

(19,699)

372,694

 

 Principal borrowings (repayments) on notes and

 

 

 

 

 Convertible Debentures

20,157

(134,800)

1,009,188

 

 (Increase) Decrease in Securities available for

 

 

 

 

 Sale

 

 

50,000

 

 Contributed Capital

 

 

509,353

 

 Net Borrowings From Related Parties

 

 

1,195,196

 

 Increase (Decrease) in Notes from Affiliated party

 

 

1,000

 

 Increase in Amount due to Shareholder

 

 

 

 Net Cash Provided by (Used in) Financing

 

 

 

 

 Activities

120,059

271,991

6,918,279

 

 

 

 

 Net Increase (Decrease) in Cash

(87)

127

244

 

 

 

 

 Cash at Beginning of Period

331

306

-

 

 

 

 

 Cash at End of Period

$ 244

$433

$  244


The accompanying Notes are an Integral Part of these Financial Statements



4






BIO-MATRIX SCIENTIFIC GROUP, INC.

(A Development Stage Company)

Notes to condensed consolidated Financial Statements

As of March 31, 2012


NOTE 1. BASIS OF PRESENTATION


The interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.


These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these condensed consolidated interim financial statements be read in conjunction with the financial statements of the Company for the year ended September 30, 2011 and notes thereto included in the Company's 10-K annual report. The Company follows the same accounting policies in the preparation of interim reports.


Results of operations for the interim periods are not indicative of annual results.


A. BASIS OF ACCOUNTING

 

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30, year-end.


B. PRINCIPLES OF CONSOLIDATION

 

The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, BMSG, a Nevada corporation and a wholly owned subsidiary, and Entest BioMedical, Inc., (“Entest”), which was a majority owned subsidiary under common control and a Nevada corporation up to February 3, 2011.  Significant inter-company transactions have been eliminated.


C. USE OF ESTIMATES

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

D. DEVELOPMENT STAGE

 

The Company is a development stage company devoting substantially all of its efforts to establish a new business.


E. CASH EQUIVALENTS

 

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.


F. PROPERTY AND EQUIPMENT


Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.




5






G. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

 

Level 1:  Quoted prices in active markets for identical assets or liabilities

 

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

 

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company’s financial instruments as of March 31, 2012 consisted of $189,732 of Notes Payable, $372,694 of Convertible Notes payable (including discount attributable to beneficial conversion feature) and $59,740 due to Entest BioMedical.  The fair value of all of the Company’s financial instruments as of December 31, 2011 were valued according to the Level 2 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company


H. INCOME TAXES


The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.


The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2011 and 2010, the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

 

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

 

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

 

I.  BASIC EARNINGS (LOSS) PER SHARE

 

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.


Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.




6






NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS


In February 2010, the FASB issued ASU No. 2010-09, “Subsequent Events (ASC Topic 855), Amendments to Certain Recognition and Disclosure Requirements.” This Standard update requires a SEC Filer to (1) evaluate subsequent events through the date that the financial statements are issued or available to be issued, (2) defines “SEC Filer” as an entity that is required to file or furnish its financial statements with either the SEC or, with respect to an entity subject to Section 12(i) of the Securities Exchange Act of 1934, as amended, the appropriate agency under that Section, (3) not be bound to disclosing the date through which subsequent events have been evaluated, (4) note the definition of public entity is not longer defined nor necessary for Topic 855, (5) note the scope of the reissuance disclosure requirements is refined to include revised financial statements only. These Updates are effective for interim or annual periods ending after June 15, 2010. ASU No. 2010-09 has no effect on the Company’s financial position, statements of operations, or cash flows at this time.


In January 2010, the FASB issued ASU No. 2010-08, “Technical Corrections to various Topics.” This Standard is being updated to eliminate outdated or inconsistent GAAP standards and to clarify the Boards original intent mainly with regards to derivatives and hedging. This is effective for the first reporting period (including interim periods) beginning after issuance. ASU No. 2010-08 has no effect on the Company’s financial position, statements of operations, or cash flows at this time.


In January 2010, the FASB issued ASU No. 2010-06, “Improving Disclosures about Fair Value Measurements” related to ASC Topic 820-10.  This update requires new disclosures to; transfers in or out of Levels 1 and 2, activity in Level 3fair value measurements, Level of disaggregation, and disclosures about inputs and valuation techniques. This amendment will be effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. ASU No. 2010-06 has no impact on the Company’s results of operations, financial condition or cash flows.

 

In January 2010, the FASB issued ASU No. 2010-01, amends SFAS No. 168, The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles. This Standard codified in ASC 105 is being modified to include the authoritative and non-authoritative levels of GAAP. This amendment is effective for financial statements issued for interim and annual periods ending after September 15, 2009. ASU No. 2010-01 has no effect on the Company’s financial position, statements of operations, or cash flows at this time.

 

In January, 2010, the FASB issued ASU 2010-06, Improving Disclosures about Fair Value Measurements. The standard amends ASC Topic 820, Fair Value Measurements and Disclosures to require additional disclosures related to transfers between levels in the hierarchy of fair value measurement. The standard does not change how fair values are measured. The standard is effective for interim and annual reporting periods beginning after December 15, 2009. As a result, it is effective for the Company in the first quarter of fiscal year 2010. The Company does not believe that the adoption of ASU 2010-06 will have a material impact on consolidated its financial statements.

 

In June 2009, the FASB issued new guidance which is now part of ASC 105-10 (formerly Statement of Financial Accounting Standards No. 168, The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles). ASC 105-10 replaces FASB Statement No. 162, "The Hierarchy of Generally Accepted Accounting Principles", and establishes the FASB Accounting Standards Codification as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles. ASC 105-10 is effective for interim and annual periods ending after September 15, 2009. The adoption of ASC 105-10 did not have a material impact on the Company’s financial statements.

 

In June 2009, the FASB amended ASC 810 (formerly Statement of Financial Accounting Standards No.167, Amendments to FASB Interpretation No. 46(R)).  The amendments include: (1) the elimination of the exemption for qualifying special purpose entities, (2) a new approach for determining who should consolidate a variable-interest entity, and (3) changes to when it is necessary to reassess who should consolidate a variable-interest entity.  ASC 810 is effective for the first annual reporting period beginning after November 15, 2009 and for interim periods within that first annual reporting period. The Company will adopt ASC 810 in fiscal 2010. The Company does not expect that the adoption of ASC 810 will have a material impact on its financial statements.




7






In June 2009, the FASB amended ASC 860, (formerly SFAS No. 166, Accounting for Transfers of Financial Assets, an amendment to SFAS No. 140).  ASC 860 eliminates the concept of a “qualifying special-purpose entity,” changes the requirements for derecognizing financial assets, and requires additional disclosures in order to enhance information reported to users of financial statements by providing greater transparency about transfers of financial assets, including securitization transactions, and an entity’s continuing involvement in and exposure to the risks related to transferred financial assets. ASC 860 is effective for fiscal years beginning after November 15, 2009. The Company will adopt ASC 860 in fiscal 2010. The Company does not expect that the adoption of ASC 860 will have a material impact on its financial statements.


NOTE 3. PROPERTY AND EQUIPMENT


 Property and equipment as of December 31, 2011 consists of the following:


 

 

 

Acquisition cost:

Estimate useful life (year)

 

 

 

 

Office equipment

3 to 5

7,250

Computer

3

16,207

 

 

 

Subtotal

 

23,457

Less accumulated depreciation

 

(2,668)

Total

 

$US   20,789


Depreciation expenses were $0 and $ 0 for the year ended September 30, 2011 and six months ended march 31, 2012, respectively. With the exception of one computer which is fully depreciated, no property and equipment has yet to be utilized in production therefore no depreciation shall be recognized until usage commences.


NOTE 4. OPTIONS AND WARRANTS

 

As of March 31, 2012 the Company has no outstanding exercisable warrants or options.


NOTE 5. GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $42,182,649 recognized upon the deconsolidation of Entest, The Company generated net losses of $ 14,600,936 (including $536,961 of Net Losses attributable to non-controlling interest in Entest and $663,649 in Equity in Net Losses of Entest) during the period from August 2, 2005 (inception) through March 31, 2012. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.


NOTE 6. INCOME TAXES

 

As of December 31, 2011


 

 

Deferred tax assets:

 

Net operating tax carry forwards

$  5,123,843

Other

-0-

Gross deferred tax assets

5,123,843

Valuation allowance

(5,123,843)

 

 

Net deferred tax assets

$  -0-




8






As of  March 31 ,  2012 the Company has a  Deferred Tax Asset of  $5,123,843 completely attributable to net operating loss carry forwards  of approximately $14,639,552  ( which expire 20 years from the date the loss was incurred) consisting  of

 

(a) $38,616, of Net Operating Loss Carry forwards acquired in the reverse acquisition of BMSG and

 

(b) $14,600,936 attributable to Bio-Matrix Scientific Group, Inc. a Delaware corporation, BMSG and Entest

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, the reverse acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0.


NOTE 7. RELATED PARTY TRANSACTIONS


Between October 1, 2011 and March 31, 2011 David R. Koos, the Company’s Chairman and CEO, made net loans to the Company totaling $16,357. The total amount owed by the Company to Mr. Koos as of March 31, 2011 is $16,357. The Company is also indebted as of March 31, 2012 to Bombardier Pacific Ventures, a company controlled by Mr. Koos, in the amount of $36,281. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum.


On June 15, 2009 Entest entered into an agreement with the Company whereby Entest has agreed to sublease approximately 3,000 square feet of office space from the Company for a term of 3 years for consideration consisting of monthly rental payments of $4,100 per month.  Beginning October 2010 Entest has been paying rental expenses directly to the owner of the subleased space and is currently carrying a balance of $59,500 of rental expenses prepaid to the Company.  Between January 25, 2012 and February 14, 2012 the Company became indebted to Entest in the amount of an additional $240 for expenses paid on behalf of the Company by Entest.


NOTE 8. NOTES PAYABLE


 

 

 

 

December 31,

2011

September 30,

2011

 

 

 

Bio Technology Partners Business Trust

27,800

24,100

Bombardier Pacific Ventures (Note 7)

36,281

36,281

Venture Bridge Advisors

109,294

109,294

David Koos (Note 7)

16,357

--

Notes Payable by  Entest BioMedical derecognized upon deconsolidation of Entest BioMedical

 

 

Notes payable

$        189,732

$        169,575

Due to Affiliate

$          59,740

$          59,500

Convertible Notes Payable (Note 10)

$        391,201

$        313,701


Both of Bio-Technology Partners Business Trust and Venture Bridge Advisors have provided lines of credit to the Company in the amount of $700,000 each or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion. The unpaid principal of these lines of credit bear simple interest at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender.


All loans to the Company made by either of David R. Koos or Bombardier Pacific Ventures are due and payable at the demand of Koos or Bombardier and bear simple interest at a rate of 15% per annum.





9






The Amount Due to affiliate represents

(a)

rent prepaid to the Company by Entest BioMedical pursuant to a sublease agreement entered into by and between the Company and Entest BioMedical on June 15, 2009.  Beginning October 2010 Entest has been paying rental expenses directly to the owner of the subleased space and as of the Company’s fourth fiscal quarter both of the Company and Entest BioMedical have agreed to void the terms and conditions of the sublease. $59,500 previously paid to the Company by Entest BioMedical to repay rental expenses is currently due and payable at the demand of Entest BioMedical. This amount accrues no interest.  

(b)

$240 for expenses paid on behalf of the Company by Entest Biomedical.


NOTE 9. STOCKHOLDERS' EQUITY


The stockholders' equity section of the Company contains the following classes of capital stock as March 31, 2012:


Preferred stock, $ 0.0001 par value; 20,000,000 shares authorized:

2,975,478 preferred shares issued and outstanding.

4,852 Series AA Preferred Shares issued and outstanding.

725,409 Series B Preferred Shares issued and outstanding.

 

* Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 72,189,747 shares issued and outstanding.


NOTE 10. CONVERTIBLE DEBENTURES


On November 14, 2007 the Company sold a $50,000 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $50,000 to one purchaser.

 

Interest on the Convertible Debenture shall accrue at a rate of 12% per annum based on a 365 day year. The Company shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 12% per annum, payable on the maturity Date, which is November 14, 2009.

 

At any time subsequent to the expiration of a six month period since either of:

 

(i)           that Registration Statement, as amended, filed with the SEC on Form SB-2 relating to the sale of an aggregate of 17,195,263 shares of the common stock of the Company  by certain selling shareholders (the “Selling Shareholders Registration Statement”) has been declared effective by the SEC or

 

(ii)          the Selling Shareholder Registration Statement has been withdrawn by the Company, the holder may convert the Convertible Debenture, in whole but not in part, into the Company’s common shares at the conversion rate of $0.15 per Share.

 

Subsequent to any conversion, the holder  shall have the right, upon written demand to Company (“Registration Demand”), to cause Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.

 

On November 30, 2007, the Company sold $75,000 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $75,000 to one purchaser.

 

Interest on the Convertible Debenture shall accrue at a rate of 12% per annum based on a 365 day year. The Company shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 12% per annum, payable on the maturity Date, which is November 14, 2009.

 

At any time subsequent to the expiration of a six month period since either of:

 

(i)           that Registration Statement, as amended,  filed with the SEC on Form SB-2 relating to the sale of an aggregate of 17,195,263 shares of  the Company’s  common stock by certain selling shareholders (the “Selling Shareholders Registration Statement”) has been declared effective by the SEC or



10






(ii)          the Selling Shareholder Registration Statement has been withdrawn by the Company.

 

The holder may convert the Convertible Debenture, in whole but not in part, into the Company’s common shares at the conversion rate of $0.15 per Share (“Conversion Shares”).


Subsequent to any conversion, the holder  shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.

 

On January 8, 2008, the Company sold $18,400 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $18,400 to one purchaser.  Interest on the Convertible Debenture shall accrue at a rate of 12% per annum based on a 365 day year.  The Company   shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 12% per annum, payable on the maturity Date, which is December 28, 2009.

 

At any time subsequent to the expiration of a six month period since either of:

 

(i)           that Registration Statement, as amended,  filed with the SEC on Form SB-2 relating to the sale of an aggregate of 17,195,263 shares of  our common stock by certain selling shareholders (the “Selling Shareholders Registration Statement”) has been declared effective by the SEC or

 

(ii)           the Selling Shareholder Registration Statement has been withdrawn by the Company.

 

The holder may convert the Convertible Debenture, in whole but not in part, into our common shares at the conversion rate of $0.15 per Share (“Conversion Shares”).

 

Subsequent to any conversion, the holder shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.

 

On January 18, 2008, the Company sold $200,000 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $200,000 to one purchaser.  Interest on the Convertible Debenture shall accrue at a rate of 14% per annum based on a 365 day year.  The Company   shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 14% per annum, payable on the maturity Date, which is January 12, 2010.

 

At any time subsequent to the expiration of a six month period since either of:

 

(i)           that Registration Statement, as amended,  filed with the SEC on Form SB-2 relating to the sale of an aggregate of 17,195,263 shares of  our common stock by certain selling shareholders (the “Selling Shareholders Registration Statement”) has been declared effective by the SEC or

 

(ii)          the Selling Shareholder Registration Statement has been withdrawn by the Company.


The holder may convert the Convertible Debenture, in whole but not in part, into our common shares at the conversion rate of $0.25 per Share (“Conversion Shares”).

 

Subsequent to any conversion, the holder shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.

 

 



11





 

On January18, 2008, the Company sold $100,000 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $100,000 to one purchaser.   Interest on the Convertible Debenture shall accrue at a rate of 14% per annum based on a 365 day year.  The Company   shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 14% per annum, payable on the maturity Date, which is January 12, 2010.

 

At any time subsequent to the expiration of a six month period since either of:

 

(i)           that Registration Statement, as amended,  filed with the SEC on Form SB-2 relating to the sale of an aggregate of 17,195,263 shares of  our common stock by certain selling shareholders (the “Selling Shareholders Registration Statement”) has been declared effective by the SEC or

 

(ii)          the Selling Shareholder Registration Statement has been withdrawn by the Company.

 

The holder may convert the Convertible Debenture, in whole but not in part, into our common shares at the conversion price of $0.25 per Share (“Conversion Shares”).


Subsequent to any conversion, the holder shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.

 

The Company shall agree to the granting of a Lien to the Holder against collateral which the Company owns or intends to purchase, namely:

 

Flow Cytometer (4 Color) (BD Facscanto)

Laboratory computer system/also for enrollments/storage tracking

Hematology Analyzer (celldyne 1800)(ABBOTT)

Laminar Flow Hood 4 ft ( Clean hood) (2)

Bench top centrifuges (2) refrigerated

Small equipment (lab set-up)

Microscope

Tube heat sealers (2 ea)

Barcode printer and labeling device

 

On February 15, 2008, the Company sold $50,000 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $50,000 to one purchaser. Interest on the Convertible Debenture shall accrue at a rate of 12% per annum based on a 365 day year.  The Company   shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 12% per annum, payable on the maturity Date, which is February 15, 2010.


At any time subsequent to the expiration of a six month period since either of:

 

(i)           that Registration Statement, as amended,  filed with the SEC on Form SB-2 relating to the sale of an aggregate of 17,195,263 shares of  our common stock by certain selling shareholders (the “Selling Shareholders Registration Statement”) has been declared effective by the SEC or

 

(ii)           The Selling Shareholder Registration Statement has been withdrawn by the Company.

 

The holder may convert the Convertible Debenture, in whole but not in part, into our common shares at the conversion price of $0.10 per Share (“Conversion Shares”).

 



12






Subsequent to any conversion, the holder shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.


On March 3, 2008 the Selling Shareholder’s Registration Statement was withdrawn by the Company.

 

On March 3, 2008, the Company sold $10,000 face value convertible debenture (“Convertible Debenture”) for an aggregate purchase price of $10,000 to one purchaser.   Interest on the Convertible Debenture shall accrue at a rate of 12% per annum based on a 365 day year.  The Company   shall pay simple interest to the holder on the aggregate unconverted and then outstanding principal amount of this Convertible Debenture at the rate of 12% per annum, payable on the maturity Date, which is March 3, 2010.

 

At any time subsequent to the expiration of a six month period from March 3, 2008, the holder may convert the Convertible Debenture, in whole but not in part, into our common shares at the conversion rate of $0.15 per Share (“Conversion Shares”).


Subsequent to any conversion, the holder shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States securities and Exchange Commission (“SEC”) a Registration Statement in order that the Conversion Shares may be registered under the Securities Act of 1933, as amended, and use its reasonable best efforts to cause that Registration Statement to be declared effective by the SEC. There is no penalty to the Company in the event the registration Statement is not declared effective by the SEC.

 

On February 2, 2010 the Company issued 1,433,333 common shares in full satisfaction of a $100,000 face value of convertible debentures bearing interest at 14% per annum.

 

On February 10, 2010 the Company issued 3,000,000 shares of common stock in satisfaction of $30,000 owed by the Company to holders of the Company’s convertible debentures bearing interest at 12% per annum.

 

On March 31, 2010 the Company issued 4,000,000 shares of common stock in satisfaction of $40,000 owed by the Company to holders of the Company’s convertible debentures bearing interest at 12% per annum.


On February 17, 2011 the Company issued 1,785,714 common shares in satisfaction of $50,000 face value of convertible debentures.


On December 19, 2011, the Company issued a convertible promissory  note in the amount of $50,000 which was funded on  December 22, 2011. The note bears an interest rate of eight percent (8%), matures on September 19, 2012 and may be converted after 180 days from execution of this note for shares of the Company’s common stock. The note may be converted at a forty five percent (45%) discount to the average of the lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. The issuance of the note amounted in a beneficial conversion feature of $40,909  which  is  amortized under the Interest Method.


On February 28, 2012, the Company issued a convertible promissory  note in the amount of $27,500 which was funded on  March 6, 2012. The note bears an interest rate of eight percent (8%), matures on November 30, 2012 and may be converted after 180 days from execution of this note for shares of the Company’s common stock. The note may be converted at a forty five percent (45%) discount to the average of the lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date.


At December 31, 2011, the following convertible debentures remain outstanding:


(a) $230,301 bearing simple interest at 14% per annum convertible into the Company’s common stock at $0.025 per share.


(b) $83,000 bearing simple interest at 12% per annum convertible into the Company’s common stock at $0.025 per share.



13






(c) $77,500 bearing simple interest at 8% per annum convertible into the Company’s common stock after 180 days from execution at a forty five percent (45%) discount to the average of the lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date.


 Convertible Debentures described in (a) and (b) are currently due and payable. The holders have not made a demand for payment


NOTE 11. COMMITMENTS AND CONTINGENCIES


On August 16, 2010 a  Complaint  (“Complaint”)  was filed  in the Superior Court of the State of California, County of San Diego Central Division  against the Company,  the Company’s Chairman,   Freedom Environmental Services, Inc. and the BMXP Holdings Inc.  Shareholder’s Business Trust, a Nevada Business Trust (collectively “Defendants”) by Princeton Research, Inc. and Jan Vandersande  (collectively “Plaintiffs”) seeking to recover general damages in excess of $25,000, punitive damages in excess of $25,000 and attorney’s fees. The Complaint alleges breach of fiduciary duty of loyalty, fraud and deceit in connection with the late distribution of  shares of the Company to beneficiaries  of the BMXP Holdings Inc.  Shareholder’s Business Trust.


On June 29, 2011 the Company and BMXP Holdings Inc.  Shareholder’s Business Trust entered into a settlement agreement with the Plaintiffs (“Settlement”) whereby litigation was dismissed with prejudice and a general release of claims  was granted to the Defendants by the Plaintiffs and to the Plaintiffs by the Defendants.


Pursuant to the Settlement, the Plaintiffs will be granted one year to exclusively identify for the Company companies suitable for merger with or acquisition by the Company (“Target Companies”) provided however that the Company may also identify Target Companies over the term of the Settlement.


In the event that the Company completes a merger or acquisition of a Target Company identified by the Plaintiffs (“Transaction”) , the Plaintiffs shall be compensated in accordance with the terms and conditions of that Transaction.


In the event that the Company completes a merger or acquisition of a Target Company that is not identified by the Plaintiffs within one year from June 27, 2011 or in the event controlling interest in the Company is sold within one year from June 27, 2011  then Plaintiffs shall be entitled to receive the greater of:


 

(a)

5% of any consideration received by the Company and Bombardier Pacific Ventures in connection with such merger or sale  or

 

(b)

$25,000 in cash


In the event that an acquisition, merger or sale as contemplated under the Settlement is not completed within one year from June 27, 2011 the Plaintiffs shall receive $30,000 from the Company.


On February 3, 2011, a Complaint (“Complaint”) was filed in the U.S. District Court Middle District of the State of Pennsylvania against the Company, the Company’s Chairman and Entest. by 18KT.TV LLC (“Plaintiffs”). The Complaint is seeking damages from the Company and Entest in excess of $125,000 and alleges breach of contract, unjust enrichment and breach of implied in fact contract by the Company and Entest in connection with agreements entered into with the plaintiffs by both the Company and Entest.


On  October 24,2011 a  Complaint  (“Complaint”)  was filed  in the Superior Court of the State of California, County of San Diego Central Division  against the Company,  the Company’s Chairman,  and American Stock Transfer and Trust Company LLC by Rick Plote. The Complaint seeks damages from the defendants jointly and severally of no less than $615, 000 and alleges breach of written agreement, breach of written guarantee and fraud in connection with the defendant’s failure to transfer 4,000,000 common shares of the Company beneficially owned by the company’s Chairman and CEO and pledged by the Company’s Chairman to secure payment of a promissory note issued by an unaffiliated third party.  


NOTE 13. DECONSOLIDATION OF ENTEST BIOMEDICAL, INC.


Effective February 4, 2011 the Company’s ownership of Entest BioMedical, Inc. fell to approximately 49%. and commencing February 4, 2011 the Company’s financial statements reflect the Company’s ownership of Entest under the equity method of accounting. A gain of $42,182,649 was recognized in accordance with ASC 810-10-40-5. Fair value of the Company’s investment in Entest BioMedical, Inc. resulting from deconsolidation was calculated utilizing Level 1 inputs in accordance with ASC 820. As of February 29, 2012 , the end of Entest’s last fiscal quarter, the Company’s ownership of Entest is approximately 38%.



14






Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


CERTAIN FORWARD-LOOKING INFORMATION

 

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concern industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission, including the Company's most recent Form 10Kfor the year ended September 30, 2011. All references to” We”, “Us”,  “Company” or the “Company” refer to Bio-Matrix Scientific Group, Inc.


Material Changes in Financial Condition:


As of March  31, 2012 we had cash on hand of $244  and as of September 30, 2011  we had cash on hand of $331.


The decrease in cash on hand of approximately 26% is primarily attributable to cash expended to fund the operations of the Company offset by  borrowings.


As of March 31, 2012 we had Notes Payable of $189,732 and as of September 30, 2011 we had Notes Payable of $169,575.


This increase of approximately 12% is primarily attributable to additional net borrowings incurred by us  of approximately $20,157.

 

As of March 31, 2012 we had Accrued Payroll of $777,000 and as of September 30, 2011 we had Accrued Payroll of $627,000


This increase of approximately 24% is primarily attributable to increases in employee compensation which have accrued and have not yet been paid of  $150,000.  


As of March 31, 2012 we had Accrued Interest of $203,869  and as of September 30, 2011 we had Accrued Interest  of $154,930.


This increase of approximately 32% is primarily attributable to an increase in interest accrued yet unpaid on Notes and Convertible Notes  issued by the Company

 

As of March 31, 2012 we had $372,694  in Convertible Notes payable  and as of September 30, 2011 we had $313, 701  in  Convertible Notes payable.


This increase of approximately 19 % is primarily attributable to

(a)

the issuance by the Company of a convertible promissory note in the amount of $50,000 which was funded on  December 22, 2011 for  which a beneficial conversion feature of $40,909 was recognized  which  is  amortized under the Interest Method and of which $18,507 remains unamortized as of March 31, 2012.

(b)

the issuance by the Company of a convertible promissory  note in the amount of $27,500  on February 28, 2012 which was funded on  March 6, 2012.


Material Changes in Results of Operations


Revenues were -0- for the quarter ending March 31, 2012 and -0- for the same quarter ending 2011. Net Losses were $504, 734  for the three months ended March 31, 2012. Net Income was 41,991,406 for the same quarter ending 2011 .



15






The difference is primarily attributable to the recognition by the Company of a noncash gain of $42,182, 649 resulting from the deconsolidation of Entest BioMedical, Inc. during the quarter ended March 31, 2011  as well as Other Income of 146,791 recognized by the Company in the quarter ended march 31, 2011 resulting from resulting from the confirmation in writing from the Company’s former landlord informing the Company that no further payment is required to be made by the Company for outstanding rental liabilities resulting in the elimination of $146,791 of Payables owed by the Company.


For the quarter ended March 31, 2012:


(a)

 Consulting and interest expenses increased approximately 500% and 300% respectively when compared to the same period ended 2011

(b)

General and Administrative Expenses decreased approximately 24% when compared to the same period ended 2011

(c)

Equity in Net Losses of the Company’s unconsolidated subsidiary, Entest Biomedical, inc., increased approximately 238% when compared to the same period ended 2011.


Revenues were -0- for the six months  ending March 31, 2012 and -0- for the same period  ending 2011. Net Losses were $718, 407  for the six  months ended March 31, 2012. Net Income was 41,725, 606  for the same period ending 2011 .


The difference is primarily attributable to the recognition by the Company of a noncash gain of $42,182, 649 resulting from the deconsolidation of Entest BioMedical, Inc. during the quarter ended March 31, 2011 as well as Other Income of 146,791 recognized by the Company in the quarter ended march 31, 2011 resulting from resulting from the confirmation in writing from the Company’s former landlord informing the Company that no further payment is required to be made by the Company for outstanding rental liabilities resulting in the elimination of $146,791 of Payables owed by the Company.


For the six months ended March 31, 2012 our Research and Development Expenses decreased 100% when compared to the same period ended 2011.For the six months ended March 31, 2012 our General and Administrative Expenses decreased 73% when compared to the same period ended 2011. For the six months ended March 31, 2102 our consulting expenses and interest expenses increased 80% and108 % respectively when compared to the same period ended 2011.


Liquidity and Capital Resources


As of March 31, 2012, we had $244  cash on hand and current liabilities of $1,763,322   such liabilities consisting of Accounts Payable, Notes Payable, Accrued Payroll Taxes, Convertible Notes payable net of unamortized discount, Amounts due to Affiliated Parties, Accrued Expenses  and Accrued Interest.

 

We feel we will not be able to satisfy our  cash requirements over the next twelve months and shall be required to seek additional financing.

 

At this time, we plan to fund our financial needs through equity private placements of common stock. (No plans, terms, offers or candidates have yet been established and there can be no assurance that the company will be able to raise funds on terms favorable to us or at all.) We cannot assure that we will be successful in obtaining additional financing necessary.  We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate.  For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances.


We were not party to any material commitments for capital expenditures as of the end of the quarter ended March 31 , 2012.



16






Item 3. Quantitative and Qualitative Disclosures About Market Risk


As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.


Item 4. Controls and Procedures.


Evaluation of Disclosure Controls and Procedures


As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer/Principal Financial Officer has concluded that the Company's disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.


Changes in Internal Controls over Financial Reporting


In connection with the evaluation of the Company's internal controls during the period commencing on January 1, 2012 and ending March 31, 2012, David Koos, who is both the Company's Principal Executive Officer and Principal Financial Officer has determined that there were no changes to the Company's internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reporting.  


PART II - OTHER INFORMATION


Item 1. Legal Proceedings.


On  October 24,2011 a  Complaint  (“Complaint”)  was filed  in the Superior Court of the State of California, County of San Diego Central Division  against the Company,  the Company’s Chairman,  and American Stock Transfer and Trust Company LLC by Rick Plote. The Complaint seeks damages from the defendants jointly and severally of no less than $615, 000 and alleges breach of written agreement, breach of written guarantee and fraud in connection with the defendant’s failure to transfer 4,000,000 common shares of the Company beneficially owned by the company’s Chairman and CEO and pledged by the Company’s Chairman to secure payment of a promissory note issued by an unaffiliated third party.  


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.


No unregistered sales of equity securities were conducted by the Company during the period beginning  January 1, 2012 and ending March 31, 2012.


Item 3. DEFAULTS UPON SENIOR SECURITIES


None.

  

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


None.


Item 5. OTHER INFORMATION


On February 28, 2012, the Company issued a convertible promissory  note in the amount of $27,500 which was funded on  March 6, 2012. The note bears an interest rate of eight percent (8%), matures on November 30, 2012 and may be converted after 180 days from execution of this note for shares of the Company’s common stock. The note may be converted at a forty five percent (45%) discount to the average of the lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date.



17






Item 6. EXHIBITS

  

10.1

8% Convertible Note in the Amount of $27,500

 

 

31.1

Certification of Chief Executive Officer

 

 

31.2

Certification of Acting Chief Financial Officer

 

 

32.1

Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

32.2

Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.











18






SIGNATURES


In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

Bio-Matrix Scientific Group, Inc.

 

a Delaware corporation

 

 

By:

/s/ David R. Koos

 

David R. Koos

 

Chief Executive Officer

 

 

 

Date: April 23,2012

 

 

 

 











 

 

 


 




19